Meningococcal disease

Meningococcal disease is the invasive disease caused by the human pathogen Neisseria meningitidis ^[1]. In the source material, it is described through the lens of invasive meningococcal disease (IMD), a condition that usually presents as meningitis, bacteremia, or sepsis ^[1]. The available sources do not provide additional source-backed characterization of noninvasive syndromes, pathogenesis, or laboratory definition, so those details are not yet available.

The source evidence identifies the usual invasive presentations as meningitis, bacteremia, and sepsis ^[1]. No further source-backed symptom chronology, complication profile, or outcome pattern is provided in the supplied material, so more detailed clinical course information is not yet available. The resistance-focused review adds that resistant isolates have increased over the last two decades, including resistance to penicillin and fluoroquinolones, which is clinically relevant to management and prevention context but does not by itself define the syndrome ^[1].

The epidemiology of invasive meningococcal disease is described as unpredictable, regionally variable, and continuously evolving ^[2]. A review of surveillance reports and published articles from 2010 to 2019 across 77 countries found that global incidence was generally low, but with substantial variation between regions in circulating serogroups ^[2]. Highest incidence was usually observed in infants, generally followed by young children and adolescents/young adults, with older adults also affected in some countries ^[2]. Globally, serogroup B was predominant in most countries, while serogroups W and Y increased in several regions during 2010 to 2019; serogroups A, B, C, W, and Y accounted for the vast majority of IMD cases ^[2].

The supplied sources do not explicitly state the transmission route or exposure mechanism for meningococcal disease, so source-backed transmission detail is not yet available. The material does indicate that the organism is a human pathogen and that surveillance and chemoprophylaxis are relevant to control, but it does not provide direct transmission wording ^[1].

The source evidence identifies infants as having the highest incidence, generally followed by young children and adolescents/young adults, with older adults also affected in some countries ^[2]. Beyond age, the supplied material does not provide additional source-backed high-risk group detail. One review notes special populations such as individuals on complement inhibitors, but this is presented as a topic of review rather than a fully characterized risk estimate in the provided snippet ^[1].

The source literature indicates that vaccines are available to prevent disease due to serogroups A, B, C, W, and Y, although these serogroups still accounted for the vast majority of IMD cases in the reviewed period ^[2]. The resistance review notes that increasing antibiotic resistance affects chemoprophylaxis and treatment options, underscoring the need for enhanced global surveillance ^[1]. No further source-backed details are available here on specific vaccine schedules, contact management, or other exposure-control measures.

In surveillance settings, meningococcal disease should be read as an invasive, serogroup-variable infection with low global incidence but marked regional and age-related heterogeneity ^[2]. The source literature emphasizes that serogroup distribution can shift over time, including notable increases in W and Y in several regions, so trend monitoring should consider both incidence and serogroup composition ^[2]. The emergence of antibiotic-resistant isolates, especially penicillin- and fluoroquinolone-resistant strains, is also a relevant monitoring signal because it may affect chemoprophylaxis and treatment policy ^[1].

1. 1 Rodriguez E et al. Progression of antibiotic resistance in Neisseria meningitidis. Clin Microbiol Rev. 2025 Mar 13. PMID: 39887238. doi: 10.1128/cmr.00215-24. PubMed: https://pubmed.ncbi.nlm.nih.gov/39887238/
2. 2 Pardo de Santayana C et al. Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review. Epidemiol Infect. 2023 Mar 6. PMID: 37052295. doi: 10.1017/S0950268823000328. PubMed: https://pubmed.ncbi.nlm.nih.gov/37052295/
3. 3 PubMed record 1. PubMed indexed record. 2024 Mar 19. PMID: 38843370. PubMed: https://pubmed.ncbi.nlm.nih.gov/38843370/
4. 4 Meningococcal disease. African Journal of Emergency Medicine. 2011. doi: 10.1016/j.afjem.2011.07.007. DOI: https://doi.org/10.1016/j.afjem.2011.07.007
5. 5 Meningococcal Disease. Infection Prevention and Control. 2008. doi: 10.1002/9780470988091.ch13. DOI: https://doi.org/10.1002/9780470988091.ch13
6. 6 Meningococcal Disease. Clinical Nurse Specialist. 2018. doi: 10.1097/nur.0000000000000347. DOI: https://doi.org/10.1097/nur.0000000000000347

ICD-10

ICD-11

Total cases

17K

Total deaths

214

Peak month

2018-01

Coverage

9 reporting countries · 2000-01-01 → 2026-06-20